COMPANY NEWS

March 3, 2023

CureLab Receives $3M from Prominent Biotech Investor Dr. John Ballantyne

Ballantyne is the co-founder and former chief scientific officer of Aldevron, a leading manufacturer of plasmids and other biologicals

November 5, 2022

Novermber 5, 2022

Biotech Internship Opportunity! FDA/USDA liaison

CureLab Oncology and CureLab Veterinary are looking for interns to work with our FDA/USDA team on regulatory activities.

September 14, 2022

CureLab Research Results With Cats Published in Animals Journal

Results published by CureLab scientists with the University of Camerino support targeting mammary gland cancers in cats via p62 plasmid

May 19, 2022

Review Paper Published by CureLab Veterinary and University of Camerino Shows Additional Opportunities for Use of Elenavet in Treating Domestic Animals

CureLab Veterinary is preparing to start the USDA-CVB process with its patented product and is raising funds to complete the USDA-CVB licensing process in the United States

May 12, 2022

CureLab Veterinary’s DNA Plasmid, Elenavet, Designated a Biologic Veterinary Product by the European Medicines Agency

CureLab Veterinary plans to obtain regulatory approval in Europe, a market with significant revenue potential

May 6, 2022

CureLab Veterinary Secures Patent Protection for P62 Plasmid Therapeutic in South Korea

Patent registration in South Korea enables CureLab Veterinary to pursue a market with high commercial potential

April 23, 2022

University of Camerino Signs Strategic Partnership with CureLab Veterinary to Revolutionize Cancer Treatment for Companion Animals

The university is also renewing its agreement with CureLab Oncology to support its phase II clinical trials